Multiple Myeloma

Carfilzomib(Kyprolis), a new FDA approved drug for multiple myeloma

Carfilzomib(Kyprolis) is a newly approve drug for multiple myeloma. (Onyx Pharmaceuticals) is similar to Velcade.  KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is a proteasome inhibitor that inhibits the breakdown of proteins

Read more
Super-BEAM for Myeloma

BEAM Super is a 9 high dose chemo drugs over 5 days chemo regime. It is unique to the University of Arkansas Myeloma center, an institution which is on the leading age of developing new myeloma treatments. The regimen comprises BCNU at 300mg/m2 on day 1, etoposide 200mg/m2 on days 1-4; cytarabine 400mg/m2 on days 1-5; melphalan 140mg/m2 on day 5 plus: bortezomib 1.0-1.3mg/m2 on days 1+4, thalidomide 100-200mg on days 1-5, dexamethasone 20-40mg days

Read more